logo

Conatus Pharmaceuticals Inc (CNAT)



Trade CNAT now with
  Date
  Headline
11/3/2016 7:39:03 AM Conatus Initiates Phase 2b ENCORE-PH Clinical Trial Of Emricasan In Patients With NASH Cirrhosis
5/5/2016 7:22:11 AM Conatus Pharmaceuticals Q1 Net Loss Widens To $7.3 Mln From $6.0 Mln Last Year
4/4/2016 7:32:57 AM Conatus Pharmaceuticals Appoints Edward Smith III As SVP, Regulatory Affairs And Quality Assurance
3/30/2016 7:37:37 AM Conatus Pharmaceuticals Announces Acceptance Of Abstracts For EASL Meeting
2/3/2016 7:38:22 AM Conatus Says FDA Granted Fast Track Designation For Development Of Emricasan In NASH Cirrhosis
1/11/2016 7:39:09 AM Conatus Begins Phase 2b ENCORE-NF Clinical Trial Of Emricasan In Patients With NASH Fibrosis
1/5/2016 4:10:52 PM Conatus Pharmaceuticals Trading Expected To Resume At 4:35 PM ET
1/5/2016 4:01:56 PM Conatus Pharmaceuticals Trading Halted Pending News
11/14/2015 12:05:57 PM Conatus Pharma Expects To Initiate ENCORE Trials On Staggered Basis Over Next 15 Months
10/20/2015 10:11:19 AM Conatus Pharma Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting
9/23/2015 4:10:40 PM Conatus Pharmaceuticals Trading Expected To Resume At 4:30 PM ET